Skip to main content
. 2015 Aug 19;29(10):1498–1509. doi: 10.1210/me.2015-1133

Figure 1.

Figure 1.

Sirt1 inhibits osteoclast formation. Representative pictures (A) and number (B) of TRAP-positive multinucleated osteoclasts derived from BMMs cultured with M-CSF (30 ng/mL), RANKL (30 ng/mL), and the indicated doses of Sirt1 activators for 4.5 days. C, Raw264.7 cells cultured with RANKL (50 ng/mL) and the indicated doses of SRT3025 for 5 days. D, BMMs from WT or Sirt1f/f mice, infected with Ad-Cre to delete Sirt1, were cultured with RANKL (30 ng/mL) in the presence or absence of SRT3025 (10μM) for 5 days. E–G, Raw264.7 cells were transfected with empty vector or with a Flag-tagged Sirt1 plasmid and cultured with RANKL (50 ng/mL) for 5 days. E, Sirt1 levels detected by Western blotting. Representative pictures (F) and number (G) of TRAP-positive multinucleated osteoclasts. Bars represent mean ± SD; *, P < .05 vs untreated cells or empty vector by Student's t test; #, P < .05 by two-way ANOVA.